JP2019533018A - 慢性炎症状態の処置の為の肥満細胞安定剤 - Google Patents

慢性炎症状態の処置の為の肥満細胞安定剤 Download PDF

Info

Publication number
JP2019533018A
JP2019533018A JP2019542351A JP2019542351A JP2019533018A JP 2019533018 A JP2019533018 A JP 2019533018A JP 2019542351 A JP2019542351 A JP 2019542351A JP 2019542351 A JP2019542351 A JP 2019542351A JP 2019533018 A JP2019533018 A JP 2019533018A
Authority
JP
Japan
Prior art keywords
dosage form
mast cell
subject
compound
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019542351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533018A5 (OSRAM
Inventor
パリッシュ ハイド−デルイスシャー，ロビン
パリッシュ ハイド−デルイスシャー，ロビン
Original Assignee
エマーゴ セラピューティクス，インク．
エマーゴ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エマーゴ セラピューティクス，インク．, エマーゴ セラピューティクス，インク． filed Critical エマーゴ セラピューティクス，インク．
Publication of JP2019533018A publication Critical patent/JP2019533018A/ja
Publication of JP2019533018A5 publication Critical patent/JP2019533018A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019542351A 2016-10-18 2017-10-18 慢性炎症状態の処置の為の肥満細胞安定剤 Pending JP2019533018A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409557P 2016-10-18 2016-10-18
US62/409,557 2016-10-18
PCT/US2017/057078 WO2018075574A1 (en) 2016-10-18 2017-10-18 Mast cell stabilizers for treatment of chronic inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2019533018A true JP2019533018A (ja) 2019-11-14
JP2019533018A5 JP2019533018A5 (OSRAM) 2020-12-03

Family

ID=62019018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542351A Pending JP2019533018A (ja) 2016-10-18 2017-10-18 慢性炎症状態の処置の為の肥満細胞安定剤

Country Status (5)

Country Link
US (1) US11478463B2 (OSRAM)
EP (1) EP3528809A4 (OSRAM)
JP (1) JP2019533018A (OSRAM)
CA (1) CA3040420A1 (OSRAM)
WO (1) WO2018075574A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190073365A (ko) 2016-09-08 2019-06-26 이메르고 테라퓨틱스, 인코포레이티드 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206659A1 (en) * 2008-05-23 2011-08-25 Dennis Penn Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2014070696A2 (en) * 2012-10-30 2014-05-08 Bridge Pharma, Inc. Medicinal treatment of chronic dermal inflammatory diseases with norketotifen
WO2015020878A1 (en) * 2013-08-06 2015-02-12 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through histamine h-4 receptors
US20150272941A1 (en) * 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
WO2015147296A1 (ja) * 2014-03-27 2015-10-01 株式会社ポーラファルマ 乳化剤形の組成物の製造方法
WO2016019246A1 (en) * 2014-08-01 2016-02-04 The Johns Hopkins University Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
AU6165798A (en) 1997-02-18 1998-09-08 Bridge Pharma, Inc. Non-sedating histamine antagonist compounds, compositions and methods of use thereof
EP0977568B1 (en) 1997-04-03 2006-03-08 Bridge Pharma, Inc. Benzocycloheptathiophene compounds
US6207684B1 (en) 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
PL353586A1 (en) 1999-09-13 2003-12-01 Bridge Pharma, Inc.Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20030118670A1 (en) 2001-07-11 2003-06-26 Smith C. Steven Novel composition and method for altering allergenic protein in the environment
US20060084695A1 (en) 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
CN101541303A (zh) 2006-09-29 2009-09-23 庄臣及庄臣视力保护公司 用于治疗眼变态反应性的方法和眼科装置
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
US20100166804A1 (en) 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009088570A1 (en) 2008-01-04 2009-07-16 Sirion Therapeutics, Inc. Stable aqueous cyclosporin compositions
WO2010047681A1 (en) 2008-10-24 2010-04-29 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
US8765787B2 (en) 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
CA2754996A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2506843A4 (en) 2009-12-02 2013-04-17 Bridge Pharma Inc TREATMENT OF THE DRY EYE WITH COMPOUNDS TO INCREASE MOMENTUM DRY SECRETION
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
EP3653207A1 (en) * 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
WO2016011254A1 (en) * 2014-07-16 2016-01-21 Henry J. Legere Md, Pa Combinations of antihistamines and leukotriene antagonists and methods of use thereof
EP3267794B1 (en) 2015-02-13 2020-09-09 Yale University Biaryltriazole inhibitors of macrophage migration inhibitory factor
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
KR20190073365A (ko) 2016-09-08 2019-06-26 이메르고 테라퓨틱스, 인코포레이티드 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206659A1 (en) * 2008-05-23 2011-08-25 Dennis Penn Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2014070696A2 (en) * 2012-10-30 2014-05-08 Bridge Pharma, Inc. Medicinal treatment of chronic dermal inflammatory diseases with norketotifen
US20150272941A1 (en) * 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
WO2015020878A1 (en) * 2013-08-06 2015-02-12 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through histamine h-4 receptors
WO2015147296A1 (ja) * 2014-03-27 2015-10-01 株式会社ポーラファルマ 乳化剤形の組成物の製造方法
WO2016019246A1 (en) * 2014-08-01 2016-02-04 The Johns Hopkins University Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC GASTROENTEROL. (2015) VOL.15,ARTICLE NUMBER: 47, P.1-8, JPN6021036926, ISSN: 0004927989 *
HU, Y. ET AL.: "Mast cell-induced lung injury in mice infected with H5N1 influenza virus", JOURNAL OF VIROLOGY, vol. 86, no. 6, JPN6021028840, 2012, pages 3347 - 3356, ISSN: 0004927990 *
皮膚 (1999) VOL.41, NO.2, P.165-169, JPN6022016239, ISSN: 0004927991 *

Also Published As

Publication number Publication date
CA3040420A1 (en) 2018-04-26
WO2018075574A1 (en) 2018-04-26
US11478463B2 (en) 2022-10-25
EP3528809A1 (en) 2019-08-28
US20200215049A1 (en) 2020-07-09
EP3528809A4 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
US11072648B2 (en) Mast cell stabilizers for treatment of fever
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
US20130059876A1 (en) Liquid nasal spray containing low-dose naltrexone
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
US20200289466A1 (en) Methods and uses of nampt activators for treatment of diabetes, cardiovascular diseases, and symptoms thereof
JP2019532939A5 (OSRAM)
WO2014205159A1 (en) Poloxamer based inhalation composition
CN110604819A (zh) 控制释放组合物及其使用方法
JP2019533018A (ja) 慢性炎症状態の処置の為の肥満細胞安定剤
EP3737378B1 (en) Palonosetron eye drops for the treatment or prevention of nausea and vomiting
KR20160062130A (ko) 구토 유발을 위한 수의학적 방법
JP2019001830A (ja) 医薬
WO2024129551A1 (en) Solid dosage form of a small molecule antiviral and uses thereof
CN115957175A (zh) 一种罗替高汀长链酯缓释微晶注射液及其用途
AU2015261543C1 (en) Controlled release compositions and their methods of use
HK40011695A (en) Norketotifen for treatment of hypercytokinemia and viral infections
HK40011695B (en) Norketotifen for treatment of hypercytokinemia and viral infections
CN111432813A (zh) 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物
RU2000122127A (ru) Цитокин-зависимое лечение заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221124